Scott Gelbard on A Look at Canadian Cannabis Stocks

A Look at Canadian Cannabis Stocks

Scott Gelbard

uction

share a border, they have very The latter still considers it a as been heavily restricted in were 38 states where the egal. pening in Canada, where ed in 2018. This has led to a ustry. unding the U.S.’s marijuana still take advantage of the ket by purchasing stocks on ver the counter markets.

Tilray Brands Inc.

In May 2021, the company purchased Aphria, which was another competitor. According to them, they are the most significant player in the global cannabis industry.

In addition to producing dried marijuana, Tilray also has various cannabis oil. In December 2017, Aphria announced that it would sell its products through Shoppers Drug Mart’s website.

Canopy Growth

The company is regarded as Canada’s first unicorn in the marijuana industry. Its marijuana brand, called “Tweed,” has gained widespread recognition due to its association with rapper Snoop Dog. It debuted on the New York Stock Exchange on May 24, 2018.

TerrAscend

TerrAscend is a vertically integrated company with extensive facilities in both the U.S. and Canada. It owns various brands, such as The Apothecarium, Cage Cannabis, Kind Tree, Ilera Healthcare, and Arise Bioscience Inc.

The Cronos Group

The Cronos Group is focused on investing in companies and pot growers in the marijuana industry. It also produces its marijuana products. In addition to this, it also invests in other companies that have various types of cannabis. Some of these include COVE, a British Columbia based producer of marijuana, Lord Jones, and PEACE NATURALS.

The company ’ s stock price has gained significantly since it received a significant investment from tobacco giant Philip Morris International in 2019. This investment gave it an increased capital base.

Aurora Cannabis

The stock of Aurora Cannabis started trading on the Toronto Stock Exchange and the New York Stock Exchange in July 2017. In January 2017, it was also granted a license to sell marijuana oil. In 2018, it purchased MedReleaf, an OTC traded company, for $2.5 billion. The company then continued its acquisition strategy by purchasing another producer, the Whistler Medical Marijuana Corporation, in 2019.

Thanks for Watching!

Visit Scott Gelbard's website